Medicaid coverage
Hawaii: what Medicaid covers
Hawaii’s QUEST Medicaid program covers Wegovy for weight loss as a Tier 2 non-preferred brand, with prior authorization and a quantity limit. Zepbound and Saxenda are not named on the July 1, 2026 Preferred Drug List, so their status is unverified rather than a refusal, and members can ask the plan for an exception to a drug that is not listed.
| Drug | Position | Criteria |
|---|---|---|
| Semaglutide | Prior authorization | Wegovy is a Tier 2 non-preferred anti-obesity agent on the QUEST PDL, with prior authorization and a quantity limit |
| Tirzepatide | not checked | Zepbound is not named on the July 1, 2026 QUEST Preferred Drug List |
| Liraglutide | not checked | Saxenda is not named on the QUEST PDL; liraglutide appears only as Victoza, the diabetes product |
-
Semaglutide Prior authorization
Wegovy is a Tier 2 non-preferred anti-obesity agent on the QUEST PDL, with prior authorization and a quantity limit
-
Tirzepatide not checked
Zepbound is not named on the July 1, 2026 QUEST Preferred Drug List
-
Liraglutide not checked
Saxenda is not named on the QUEST PDL; liraglutide appears only as Victoza, the diabetes product
Sources
Every claim above is checked against the primary text, and the date is the day we last opened it.
-
1
Preferred Drug List (PDL), Hawaii QUEST Program, effective July 1, 2026 (UnitedHealthcare Community Plan of Hawaii)
UnitedHealthcare Community Plan of Hawaii (Hawaii QUEST Medicaid managed care program) Primary text read and checked Checked August 27, 2026